股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 麥迪衛康健康醫療管理科技股份有限公司 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02159 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 38,000,000,000 | HKD | | 0.00001 | HKD | | 380,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 38,000,000,000 | HKD | | 0.00001 | HKD | | 380,000 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 Mediwelcome Healthcare Management & Technology Inc. 麥迪衛康健康醫療管理科技股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2159） (1)主要交易 – 收購香港寰宇醫誠智慧科技發展有限公司100%已發行股本； 及 (2)根據特別授權配售新股份 本公司之財務顧問 萬 海 證 券（香 港）有 限 公 司 – 1 – 收購事項 董事會欣然宣佈，於2026年3月30日（聯 交 所 交 易 時 段 後），買 方（為 本 公 司 直 接 全 資 附 屬 公 司）與 該 等 賣 方 訂 立 收 購 協 議。據 此，買 方 有 條 件 同 意 收 購，而 該 等賣方有條件同意出售10,628股待售股份（相當於目標公司的全部已發行股本）， 總代價為139,772,727港元，惟須遵守收購協 ...

Group 1 - Western Cement (02233) reported a revenue of RMB 9.621 billion for the fiscal year 2025, a year-on-year increase of 15.3%, with a net profit attributable to shareholders of RMB 880 million, up 40.5% [1] - Jin Xun Resources (03636) saw its stock rise over 14% after announcing an expected comprehensive profit of approximately RMB 300 million to RMB 330 million for the fiscal year ending December 31, 2025, significantly up from RMB 202 million for the previous year [1] - LeShuShi (02698) reported a revenue of approximately USD 567 million for 2025, a 24.9% increase year-on-year, with a net profit of about USD 121 million, up 27.4% [1] Group 2 - Optical communication stocks surged, with Changfei Fiber Optic (06869) rising 7.27% and other related companies also seeing gains, as the optical communication sector's performance exceeded expectations for 2025 [2] - China Resources Beer (00291) rebounded over 4% after reporting a revenue of RMB 37.985 billion for 2025, a decrease of 1.68%, and a net profit of RMB 3.371 billion, down 28.87% [2] - Zhongguang Nuclear Mining (01164) experienced a decline of over 2% after announcing an expected decrease in pre-tax profit by approximately HKD 200 million for 2025 [2] Group 3 - Wynn Macau (01128) reported a total revenue of HKD 24.418 billion for the fiscal year ending December 31, 2025, a year-on-year increase of 3.39%, but a net profit attributable to shareholders of HKD 1.63 billion, down 49.05% [2] - Li Fu China (02136) saw its stock drop nearly 9% after reporting a revenue of RMB 1.211 billion for 2025, a decrease of 3.35%, and a net loss of RMB 31.131 million, widening by 54.84% [3] - Maidi Weikang (02159) reported a revenue of RMB 468 million for the fiscal year ending December 31, 2025, a year-on-year increase of 45.55%, with a net profit of RMB 9.988 million, recovering from a loss of RMB 45.245 million in the previous year [4] Group 4 - Estée Lauder (EL.US) is in talks with Spanish beauty group Puig regarding a potential merger, which led to a nearly 8% drop in its stock price [5] - Energy storage stocks collectively rose, with CleanSpark (CLSK.US) up 6.17%, as the ongoing geopolitical tensions are expected to accelerate global energy transition [5] - Gold stocks rebounded, with AngloGold (AU.US) rising 7.01%, as spot gold prices recovered after a significant drop [6]

Financial Performance - Total revenue for the year ending December 31, 2025, is projected to be RMB 468,019,000, an increase of 45.5% from RMB 321,558,000 in 2024[3] - Gross profit for 2025 is expected to be RMB 94,710,000, representing a gross margin of 20.2%, compared to RMB 51,004,000 in 2024[3] - The company reported a net profit of RMB 6,982,000 for 2025, a significant recovery from a net loss of RMB 46,947,000 in 2024[3] - Basic and diluted earnings per share for 2025 are projected at RMB 4.38, compared to a loss of RMB 23.63 per share in 2024[3] - The total comprehensive income for the year is expected to be RMB 3,454,000, recovering from a loss of RMB 46,688,000 in the previous year[3] - The group reported a pre-tax profit of RMB 6,982,000 in 2025, recovering from a loss of RMB 45,171,000 in 2024[20] - The group recorded a profit of approximately RMB 7.0 million for the current year, compared to a loss of approximately RMB 46.9 million for the year ending December 31, 2024, driven by continuous growth in core business performance and a focus on higher-margin projects[58] Expenses and Cost Management - Research and development expenses increased to RMB 27,936,000 in 2025, up from RMB 18,680,000 in 2024, indicating a focus on innovation[3] - Selling and distribution expenses rose to RMB 25,857,000 in 2025, compared to RMB 20,666,000 in 2024, reflecting increased marketing efforts[3] - Administrative expenses decreased slightly to RMB 37,840,000 in 2025 from RMB 39,924,000 in 2024, indicating improved cost management[3] - The total employee costs, including salaries and benefits, were RMB 62,427,000 in 2025, down from RMB 66,845,000 in 2024[24] - The sales cost rose by about 38.0% from approximately RMB 270.6 million for the year ending December 31, 2024, to approximately RMB 373.3 million for the current year[49] - The sales expenses increased by approximately 24.6% from about RMB 20.7 million for the year ending December 31, 2024, to approximately RMB 25.8 million for the current year[52] - Financial costs increased by approximately 27.3% to about RMB 1.4 million due to higher average bank loan balances compared to the year ending December 31, 2024[57] Assets and Liabilities - Total assets for 2025 amounted to RMB 190,487 million, a slight decrease from RMB 194,088 million in 2024[4] - Current liabilities decreased to RMB 82,586 million in 2025 from RMB 117,046 million in 2024, indicating improved liquidity[4] - The net value of current assets increased significantly to RMB 73,529 million in 2025, compared to RMB 43,814 million in 2024[4] - The company reported a total equity of RMB 105,379 million in 2025, up from RMB 73,279 million in 2024, reflecting strong financial health[5] - The total liabilities decreased to RMB 82,586 million in 2025 from RMB 117,046 million in 2024, showing effective debt management[4] - As of December 31, 2025, the group had outstanding bank loans of approximately RMB 47.6 million, an increase from RMB 39.0 million as of December 31, 2024[61] - The group’s total liabilities to equity ratio improved to 45.2% as of December 31, 2025, down from 53.3% as of December 31, 2024[62] Revenue Segments - Major service revenue segments include Medical Conference Services at RMB 116,285,000 in 2025, down from RMB 158,680,000 in 2024, indicating a decline of about 26.7%[20] - The total income recognized at a point in time for 2025 is RMB 467,766,000, compared to RMB 320,566,000 in 2024, showing a substantial increase[21] - The group’s total service revenue for 2025 is RMB 468,019,000, which is a significant increase from RMB 321,558,000 in 2024[21] Customer and Market Insights - Customer A contributed 28% of total revenue in 2025, while Customer B contributed 14% in 2024, highlighting significant customer dependency[21] - The group has a single reportable segment primarily operating in China, where most of its non-current assets are located[19] - The company is focused on health management technology, suggesting a strategic emphasis on healthcare innovation[81] Strategic Initiatives and Future Outlook - The company is transitioning to an "AI Intelligent Body" strategy, focusing on AI specialized models and blockchain technology to enhance data utilization and compliance[38] - The company aims to improve service response times for NGOs, medical institutions, and pharmaceutical clients through its integrated platform[39] - The company is committed to advancing digitalization and intelligent transformation in the healthcare sector amidst a challenging market environment[36] - The company plans to focus on AI small model technology to expand its business coverage and enhance cooperation with more clients, aiming to increase business scale[43] - The business strategy includes expanding into high-value areas such as post-market surveillance and real-world studies, providing solid data support for pharmaceutical companies' new drug development decisions[44] - The company aims to break down information barriers in the healthcare sector, facilitating communication among doctors, patients, healthcare institutions, and pharmaceutical companies[43] Governance and Corporate Structure - The board of directors did not recommend any final dividend for the year[77] - The board of directors includes executive directors and independent non-executive directors, indicating a diverse governance structure[82] - The presence of multiple directors suggests a collaborative approach to decision-making within the company[82] - The involvement of independent directors may enhance corporate governance and accountability[82] - The executive team includes experienced professionals, which may contribute to effective leadership and strategic direction[82] Regulatory and Compliance Updates - The amendments to Hong Kong Financial Reporting Standards (HKFRS) No. 9 and No. 7 will take effect on January 1, 2026, and are not expected to have a significant impact on the group's financial statements[8] - The revisions clarify the classification and measurement of financial instruments, particularly regarding the derecognition of financial assets and liabilities[9] - The amendments provide guidance on assessing whether cash flows from financial asset contracts are consistent with basic lending arrangements[10] - The disclosure requirements for equity instruments measured at fair value through other comprehensive income have been revised, requiring entities to disclose fair value gains or losses during the reporting period[11] - HKFRS No. 18 will replace HKAS No. 1 regarding the presentation and disclosure of financial statements, introducing new requirements for the presentation of specific categories in the statement of comprehensive income[13] - The amendments to HKFRS No. 18 and other standards will come into effect on January 1, 2027, and are expected to impact the structure and presentation of future financial statements[14] - The group will reassess control over subsidiaries when any of the control criteria change, impacting the consolidation of financial statements[15]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Mediwelcome Healthcare Management & Technology Inc. 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2159） 建議修訂組織章程大綱及細則及 採納經修訂及重列組織章程大綱及細則 – 1 – 載有（ 其中包括 ）有關建議修訂及採納新組織章程大綱及細則的詳情的通函連同召 開股東週年大會的通告將於適當時候寄發予股東。 承董事會命 麥迪衛康健康醫療管理科技股份有限公司 主席兼執行董事 施煒 香港，二零二六年三月二十三日 於本公告日期，本公司執行董事為施煒先生、楊為民先生、王亮先生及鄧承英女 士；本公司非執行董事為劉夏先生；以及本公司獨立非執行董事宋瑞霖先生、王 正先生及陳會林先生。 – 2 – 本公告乃由麥迪衛康健康醫療管理科技 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Mediwelcome Healthcare Management & Technology Inc. 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2159） 盈利警告 — 虧損減少 本 公 告 乃 由 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司（「本 公 司」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「 上 市 規 則 」）第 13.09 (2) (a)條 及 香港 法例 第571 章 證券 及期 貨條 例 第XIVA 部 項下 的內 幕消 息 條文 （ 定義見上市規則 ）而刊發。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東及潛在投 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Mediwelcome Healthcare Management & Technology Inc. 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司 （於開曼群島註冊成立的有限公司） 於本公告日期，董事會由四名執行董事，即施煒先生、楊為民先生、王亮先生及 鄧承英女士；一名非執行董事，即劉夏先生以及三名獨立非執行董事，即宋瑞霖 先生、王正先生及陳會林先生組成。 主席兼執行董事 董事會會議召開日期 麥迪衛康健康醫療管理科技股份有限公司（ 連同其附屬公司統稱「本集團」）董事會 （「董事會」）謹此宣佈，謹定於2026年3月23日（ 星期一 ）舉行董事會會議，藉以審 議及批准本集團截至2025年12月31日止年度之年度業績及其發佈，考慮建議派發 末期股息（ 如有 ），以及處理任何其他事項。 香港，2026年3月11日 承董事 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 麥迪衛康健康醫療管理科技股份有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02159 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 38,000,000,000 | HKD | 0.00001 | HKD | | 380,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 38,000,000,000 | HKD | 0.00001 | HKD | | 380,000 | 本月底法定/註冊股本總額： HKD ...

Core Insights - The company, Mediwake (02159), has been focusing on the healthcare sector since its listing on the Hong Kong Stock Exchange in 2021, adapting to the transition from rapid growth to high-quality development in the medical industry [1] - Mediwake has established a strategic upgrade direction centered on "AI small models + blockchain technology," aiming to address deep-seated industry pain points through technological innovation [2] Business Foundation - The company has a strong operational foundation, serving over 3,000 tier-three medical institutions, including top hospitals like Beijing Tiantan Hospital and Fuwai Hospital, and has partnerships with 8 out of the top 10 global pharmaceutical companies [1] - The introduction of intelligent technologies has allowed Mediwake to restructure business processes significantly, optimizing personnel structure and enhancing operational efficiency [1] Technological Advancements - Mediwake's technology strategy has evolved into a dual-driven approach of "AI small models + blockchain," utilizing its self-developed "Giraffe" series digital intelligence platform for deep learning and structured processing of vast medical data [2] - The integration of blockchain technology ensures data authenticity and rights protection, leading to the successful acquisition of a data service provider certificate [2] Future Outlook - The strategic upgrade signifies a shift from being a "medical market solution provider" to a technology enterprise focused on "AI small models + blockchain" in the healthcare industry [2] - Mediwake plans to continue deepening its layout in AI small models and cutting-edge technologies, aiming to lead the healthcare service industry towards intelligence and precision, thereby creating incremental value for the sector [2]

Group 1 - The company MediWound (02159) announced the resignation of Ms. Cai Shaohui as the company secretary, effective from February 23, 2026 [1] - Ms. Chen Mingmei has been appointed as the new company secretary, authorized representative, and legal process document agent, effective from February 23, 2026 [1] - Mr. Shi Wei has resigned from the position of authorized representative appointed under Listing Rule 3.05, effective from February 23, 2026, but will continue to serve as the executive director and chairman [1] - Ms. Deng Chengying, the executive director and chief financial officer, has been appointed as the authorized representative, effective from February 23, 2026 [1]